Teva Pharma misses by $0.02, reports revs in-line; guides FY19 EPS below consensus, revs below consensus
- Reports Q4 (Dec) earnings of $0.53 per share, excluding non-recurring items, $0.02 worse than the S&P Capital IQ Consensus of $0.55; revenues fell 15.5% year/year to $4.56 bln vs the $4.52 bln S&P Capital IQ Consensus.
- GAAP gross profit margin was 43.2% in the fourth quarter of 2018, compared to 45.3% in the fourth quarter of 2017. Non-GAAP gross profit was $2,328 million in the fourth quarter of 2018, a decline of 15% from the fourth quarter of 2017.
- Co issues downside guidance for FY19, sees EPS of $2.20-2.50, excluding non-recurring items, vs. $2.82 S&P Capital IQ Consensus; sees FY19 revs of $17.0-17.4 bln vs. $17.99 bln S&P Capital IQ Consensus.